The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Astellas Pharma; Bayer; Pfizer; Sanofi
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen
Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Bhumsuk Keam
No Relationships to Disclose
 
Juergen Wolf
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Novartis; Pfizer; Roche
Research Funding - MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Novartis; Pfizer; Roche
 
Raanan Berger
No Relationships to Disclose
 
Christian Dittrich
Honoraria - Roche
Consulting or Advisory Role - Lilly; Merck; Novartis
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
 
Jean H. Hoffman-Censits
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
David Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Pfizer
Research Funding - Genentech (Inst); Millennium (Inst)
 
Ruud van der Noll
No Relationships to Disclose
 
Howard A. Burris
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Gwenaelle Gravis
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Astellas Pharma; Pfizer
Consulting or Advisory Role - Astellas Pharma
Research Funding - Bayer; Exelixis; Janssen; Novartis; Pfizer
 
Jacques Medioni
No Relationships to Disclose
 
Amir Mortazavi
Consulting or Advisory Role - Genentech
 
Pablo Maroto
No Relationships to Disclose
 
Katie Parker
Employment - Novartis
 
Xueying Chen
Employment - Novartis
 
Randi Isaacs
Employment - Novartis
 
Dean F. Bajorin
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Roche; Roche/Genentech
Research Funding - Amgen (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech